ReviewCurrent medicinal chemistry2011
Tumor-targeted drug delivery with aptamers.
Review in Current medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Aptamer-Coated PLGA Nanoparticles Selectively Internalize into Epithelial Ovarian Cancer Cells In Vitro and In Vivo.Biomolecules · 2025Article
- Structures and Applications of Nucleic Acid-Based Micelles for Cancer Therapy.International journal of molecular sciences · 2023Review
- Aptamer-Based Tumor-Targeted Diagnosis and Drug Delivery.Advances in experimental medicine and biology · 2023Review
- Targeted Delivery Methods for Anticancer Drugs.Cancers · 2022Review
- Targeting Cancer with CRISPR/Cas9-Based Therapy.International journal of molecular sciences · 2022Review
- Development and characterization of a DNA aptamer for MLL-AF9 expressing acute myeloid leukemia cells using whole cell-SELEX.Scientific reports · 2021Article
- Anti-Proliferative Effect of Doxorubicin-Loaded AS1411 Aptamer on Colorectal Cancer Cell.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Article
- Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging.Drug design, development and therapy · 2021Article
- The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells.Molecular therapy. Nucleic acids · 2019Article
- A Comprehensive Review on the Synthesis, Characterization, and Biomedical Application of Platinum Nanoparticles.Nanomaterials (Basel, Switzerland) · 2019Review
- Therapeutic targeting of gastrointestinal cancer stem cells.Regenerative medicine · 2019Review
- Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.Theranostics · 2019Article
- AptaBlocks: Designing RNA complexes and accelerating RNA-based drug delivery systems.Nucleic acids research · 2018Article
- Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.Journal of molecular medicine (Berlin, Germany) · 2018Review
- Aptamers in HIV research diagnosis and therapy.RNA biology · 2018Review
- Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention.International journal of molecular sciences · 2018Review
- Conjugate of PAMAM Dendrimer, Doxorubicin and Monoclonal Antibody-Trastuzumab: The New Approach of a Well-Known Strategy.Polymers · 2018Article
- Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells.Nature communications · 2018Article
- NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.Advanced drug delivery reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cancer is one of the leading causes of death around the world. Tumor-targeted drug delivery is one of the major areas in cancer research. Aptamers exhibit many desirable properties for tumor-targeted drug delivery, such as ease of selection and synthesis, high binding affinity and specificity, low immunogenicity, and versatile synthetic accessibility. Over the last several years, aptamers have quickly become a new class of targeting ligands for drug delivery applications. In this review, we will discuss in detail about aptamer-based delivery of chemotherapy drugs (e.g. doxorubicin, docetaxel, daunorubicin, and cisplatin), toxins (e.g. gelonin and various photodynamic therapy agents), and a variety of small interfering RNAs. Although the results are promising which warrants enthusiasm for aptamer-based drug delivery, tumor homing of aptamer-based conjugates after systemic injection has only been achieved in one report. Much remains to be done before aptamer-based drug delivery can reach clinical trials and eventually the day-to-day management of cancer patients. Therefore, future directions and challenges in aptamer-based drug delivery are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.